Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target.
BT062
SDC1
antibody-linked drug conjugate
indatuximab ravtansine
oesophageal cancer
targeted therapies
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
16
01
2023
accepted:
12
04
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Because of the poor prognosis of oesophageal adenocarcinoma (EAC), there is an urgent need for additional therapeutic approaches. Syndecan-1 (CD138) is a cell-surface heparan sulphate that is overexpressed in multiple myeloma cells and several carcinomas. Specific drugs targeting CD138 [e.g. antibody-linked drug conjugates (ADCs)] are currently being assessed; however, the significance and implication of CD138 expression in EAC is mostly unknown. In the present study, CD138 expression was assessed using immunohistochemistry, and its association with histopathological parameters and
Identifiants
pubmed: 37545626
doi: 10.3892/ol.2023.13942
pii: OL-26-2-13942
pmc: PMC10398632
doi:
Types de publication
Journal Article
Langues
eng
Pagination
356Informations de copyright
Copyright © 2023, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Folia Histochem Cytobiol. 2009;47(4):571-8
pubmed: 20430722
Matrix Biol. 2006 Sep;25(7):443-56
pubmed: 16934444
J Hematol Oncol. 2017 Jan 11;10(1):13
pubmed: 28077160
Blood Cancer J. 2020 Nov 2;10(11):110
pubmed: 33149123
Thorac Cancer. 2020 May;11(5):1121-1128
pubmed: 32154652
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Expert Rev Mol Diagn. 2018 Apr;18(4):357-370
pubmed: 29544370
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
FEBS J. 2013 May;280(10):2216-27
pubmed: 23289672
Lancet Oncol. 2007 Mar;8(3):226-34
pubmed: 17329193
Arq Bras Cir Dig. 2016 Jul-Sep;29(3):138-141
pubmed: 27759773
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Am J Gastroenterol. 2008 Nov;103(11):2694-9
pubmed: 18853967
BMC Cancer. 2019 Jan 8;19(1):38
pubmed: 30621632
Dis Markers. 2015;2015:796052
pubmed: 26420915
NPJ Breast Cancer. 2022 Aug 29;8(1):98
pubmed: 36038616
Lancet Haematol. 2021 Nov;8(11):e794-e807
pubmed: 34529955
PLoS One. 2013 Dec 31;8(12):e85737
pubmed: 24392029
Annu Rev Biochem. 1999;68:729-77
pubmed: 10872465
J Histochem Cytochem. 2011 Jun;59(6):615-29
pubmed: 21430259
Prostate. 2003 Apr 1;55(1):20-9
pubmed: 12640657
Pharm Res. 2018 Apr 17;35(6):118
pubmed: 29666962
Histol Histopathol. 2014 Feb;29(2):177-89
pubmed: 24150912
Jpn J Cancer Res. 2001 Oct;92(10):1062-73
pubmed: 11676857
Mod Pathol. 1999 Dec;12(12):1101-6
pubmed: 10619261
Cancers (Basel). 2022 Sep 30;14(19):
pubmed: 36230712
Clin Cancer Res. 2022 Dec 15;28(24):5244-5248
pubmed: 35960160
Cancer Treat Res Commun. 2021;27:100312
pubmed: 33485180
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):372-380
pubmed: 30930134
Clin Cancer Res. 2009 Jun 15;15(12):4028-37
pubmed: 19509164
Carcinogenesis. 2009 Mar;30(3):397-407
pubmed: 19126645
Methods Mol Biol. 2010;664:113-26
pubmed: 20690058
Dis Markers. 2019 Dec 23;2019:4928315
pubmed: 31976021
BMJ. 2010 Nov 26;341:c6280
pubmed: 21112905
Blood. 1998 Apr 15;91(8):2679-88
pubmed: 9531576
Oncol Rep. 2010 Apr;23(4):917-25
pubmed: 20204274
Lancet. 2002 May 18;359(9319):1727-33
pubmed: 12049861
Explor Target Antitumor Ther. 2022;3(1):27-36
pubmed: 36046357